We the undersigned, call on Parliament to ban the practice of short-selling publicly traded British companies actively engaged in the research and development of treatments for cancer and other life-threatening disorders.

The British biotech sector plays a critical role in advancing healthcare, with companies often investing significant time, capital and intellectual resources into developing novel and transformative treatments for conditions like acute myeloid/lymphoblastic leukaemias and other cancers that have been historically hard to treat. We believe that short-selling damages their ability to complete vital research in the area.